Biomemory SAS (Paris, France), a 2021 startup, has raised €5 million (about US$5.25 million) in seed investment to develop DNA digital storage.
The finance round was led by Eurekare and the French Tech Seed Fund, managed on behalf of the French State by Bpifrance.
Biomemory is competing against other startups in the same field including Iridia Inc. (see DNA-based memory startup raises $24 million) and Catalog Inc. (Boston startup finds funds for DNA computation).
Biomemory is developing a petrol-free DNA synthesis and copy process based on synthetic biology. The company has the ambition of helping data centers meet their climate challenge by reducing the energy required for archival storage.
The company pointed out that data centers’ carbon footprint is already bigger than that of civil aviation. DNA memory can replace magnetic tapes.
Applying proprietary technologies, Biomemory can produce long, bio-sourced, biocompatible and bio-secure DNA fragments that can be stored as inert polymers for
thousands of years without any energy input.
Out of CNRS/Sorbonne
Technology transfer agency SATT Lutech has granted Biomemory an exclusive worldwide licence to the two CNRS/Sorbonne University patents at the heart of this innovation. The funds raised will be used to optimize these technologies and, in particular, reduce their cost. Current DNA synthesis solutions used for medical and academic research applications cost $1/kilobyte.
Biomemory expects to reduce the cost to $1/megabyte and through further optimization
and scaling of its technologies to achieve costs of $1/terabyte. This compares to the 10-year cost of $17/terabyte for magnetic tapes.
To achieve this, Biomemory will focus on miniaturization,automation and parallelization of an end-to-end integrated and continuous microfluidic DNA assembly device.
“Biomemory has developed a unique, eco-friendly and economical technology for storing digital data on DNA, which will be able to tackle the major challenges of our future,” said Maud Henrotte, investment director at Bpifrance, in a statement issued by Biomemory.